The Signal Transduction And Targeted Therapy is reputed journal publishes research related to Biochemistry, Genetics and Molecular Biology. The ISSN of the journal is 2059-3635.
Through this web page, researchers can check the indexing, publication fee, journal quartile, and journal aim & scope.
| Journal Title | Signal Transduction and Targeted Therapy |
|---|---|
| Publisher | Nature Publishing Group |
| Publication Country | CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW |
| ISSN | 2059-3635 |
| Publication Area | Biochemistry & Molecular Biology | Cell Biology |
| Publication Language | English |
| Review Process | Anonymous peer review |
| Scopus Indexed | Yes |
The Impact Factor of Signal Transduction And Targeted Therapy in 2026 is 40.8.
The Signal Transduction And Targeted Therapy is ranked in Q1.
The Signal Transduction And Targeted Therapy is indexed in: DOAJ, Scopus, Web of Science, PubMed, Embase, UGC CARE Group 2.
There is a fee to publish in the Signal Transduction And Targeted Therapy. The publication fee is 2690 EUR; 3190 USD; 2390 GBP.
The journal also offers a fee waiver policy.
The Signal Transduction And Targeted Therapy takes an average of 5 weeks to publish research papers.
The official website of the journal is http://www.nature.com/sigtrans/.
Please visit only official website of the journal to submit research papers.